CA2741762C - A genetic marker for detection of human papillomavirus - Google Patents
A genetic marker for detection of human papillomavirus Download PDFInfo
- Publication number
- CA2741762C CA2741762C CA2741762A CA2741762A CA2741762C CA 2741762 C CA2741762 C CA 2741762C CA 2741762 A CA2741762 A CA 2741762A CA 2741762 A CA2741762 A CA 2741762A CA 2741762 C CA2741762 C CA 2741762C
- Authority
- CA
- Canada
- Prior art keywords
- hpv
- oligonucleotide
- dna
- sequence
- primers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 51
- 241000701806 Human papillomavirus Species 0.000 title claims description 177
- 239000003550 marker Substances 0.000 title description 15
- 230000002068 genetic effect Effects 0.000 title description 7
- 238000000034 method Methods 0.000 claims abstract description 99
- 210000002700 urine Anatomy 0.000 claims abstract description 97
- 239000000523 sample Substances 0.000 claims abstract description 86
- 239000013615 primer Substances 0.000 claims description 149
- 150000007523 nucleic acids Chemical class 0.000 claims description 99
- 238000003752 polymerase chain reaction Methods 0.000 claims description 87
- 102000039446 nucleic acids Human genes 0.000 claims description 73
- 108020004707 nucleic acids Proteins 0.000 claims description 73
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 230000002441 reversible effect Effects 0.000 claims description 54
- 108091034117 Oligonucleotide Proteins 0.000 claims description 49
- 238000006243 chemical reaction Methods 0.000 claims description 36
- 238000009396 hybridization Methods 0.000 claims description 34
- 230000003321 amplification Effects 0.000 claims description 33
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 33
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 239000003155 DNA primer Substances 0.000 claims description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 9
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 9
- 230000015556 catabolic process Effects 0.000 claims description 9
- 238000006731 degradation reaction Methods 0.000 claims description 9
- 239000003463 adsorbent Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000006073 displacement reaction Methods 0.000 claims description 4
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 108700004121 sarkosyl Proteins 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 230000002779 inactivation Effects 0.000 claims description 3
- 238000003753 real-time PCR Methods 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 101710163270 Nuclease Proteins 0.000 claims description 2
- 101150084750 1 gene Proteins 0.000 claims 2
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 238000007899 nucleic acid hybridization Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 26
- 101150029662 E1 gene Proteins 0.000 abstract 1
- 208000019065 cervical carcinoma Diseases 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 98
- 238000012360 testing method Methods 0.000 description 59
- 230000000295 complement effect Effects 0.000 description 35
- 238000005251 capillar electrophoresis Methods 0.000 description 33
- 108091028043 Nucleic acid sequence Proteins 0.000 description 32
- 239000000047 product Substances 0.000 description 30
- 238000003556 assay Methods 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 22
- 238000012163 sequencing technique Methods 0.000 description 22
- 239000012634 fragment Substances 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 17
- 238000009595 pap smear Methods 0.000 description 17
- 230000035945 sensitivity Effects 0.000 description 17
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 16
- 206010008342 Cervix carcinoma Diseases 0.000 description 15
- 238000001712 DNA sequencing Methods 0.000 description 14
- 201000010881 cervical cancer Diseases 0.000 description 14
- 206010008263 Cervical dysplasia Diseases 0.000 description 13
- 238000012216 screening Methods 0.000 description 12
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 9
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000001502 gel electrophoresis Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102000016911 Deoxyribonucleases Human genes 0.000 description 6
- 108010053770 Deoxyribonucleases Proteins 0.000 description 6
- 239000012614 Q-Sepharose Substances 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 108091093088 Amplicon Proteins 0.000 description 5
- 241000341655 Human papillomavirus type 16 Species 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 229910013470 LiC1 Inorganic materials 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- -1 guanidine-HC1 Chemical compound 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000007857 nested PCR Methods 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N pentofuranose Chemical group OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000007790 scraping Methods 0.000 description 3
- 238000011895 specific detection Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000892 gravimetry Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000005389 magnetism Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101150061050 CIN1 gene Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 241000341657 Human papillomavirus type 18 Species 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 238000001347 McNemar's test Methods 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000012296 in situ hybridization assay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000012729 kappa analysis Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000011310 molecular screening test Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19785008P | 2008-10-31 | 2008-10-31 | |
| US61/197,850 | 2008-10-31 | ||
| PCT/US2009/062114 WO2010051261A2 (en) | 2008-10-31 | 2009-10-26 | A genetic marker for detection of human papillomavirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2741762A1 CA2741762A1 (en) | 2010-05-06 |
| CA2741762C true CA2741762C (en) | 2018-04-03 |
Family
ID=42045205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2741762A Expired - Fee Related CA2741762C (en) | 2008-10-31 | 2009-10-26 | A genetic marker for detection of human papillomavirus |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8642261B2 (enExample) |
| EP (1) | EP2358915B1 (enExample) |
| JP (2) | JP2012507293A (enExample) |
| CN (2) | CN102333892B (enExample) |
| AU (1) | AU2009308943A1 (enExample) |
| CA (1) | CA2741762C (enExample) |
| ES (1) | ES2588251T3 (enExample) |
| HK (1) | HK1221749A1 (enExample) |
| WO (1) | WO2010051261A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013144344A2 (en) | 2012-03-30 | 2013-10-03 | Istituto Europeo Di Oncologia S.R.L. | Biomarkers for hpv infections, related diagnostic methods and kits |
| US20150376725A1 (en) * | 2013-09-04 | 2015-12-31 | Trovagene, Inc. | HPV Detection in Urine |
| TWI727156B (zh) | 2014-07-18 | 2021-05-11 | 香港中文大學 | Ｄｎａ混合物中之組織甲基化模式分析 |
| WO2017019751A1 (en) | 2015-07-27 | 2017-02-02 | The Johns Hopkins University | Method to use viral and host methylation markers for cervical cancer screening and triage in liquid prep, serum/plasma, and urine: pcr and sequencing based process methods |
| JP2020503003A (ja) | 2016-11-30 | 2020-01-30 | ザ チャイニーズ ユニバーシティ オブ ホンコン | 尿および他のサンプルにおける無細胞ｄｎａの分析 |
| WO2019013613A2 (es) | 2017-07-09 | 2019-01-17 | Hakken Enterprise Sa De Cv | Métodos y kits para determinar el riesgo de cáncer |
| TWI766225B (zh) * | 2019-01-03 | 2022-06-01 | 中國大陸商杭州諾輝健康科技有限公司 | 用於尿液樣本儲存及ｄｎａ提取之組合物及方法 |
| KR102286565B1 (ko) * | 2020-01-13 | 2021-08-05 | 대한민국 | 소변에서 결핵균 trDNA 추출용 올리고머 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2629458B2 (fr) * | 1987-07-31 | 1991-08-09 | Ire Celltarg Sa | Nouvelles sondes d'acides nucleiques specifiques de differents types de virus de papillome humain |
| US5447839A (en) * | 1988-09-09 | 1995-09-05 | Hoffmann-La Roche Inc. | Detection of human papillomavirus by the polymerase chain reaction |
| AUPN443995A0 (en) * | 1995-07-27 | 1995-08-17 | Csl Limited | Papillomavirus polyprotein |
| US20020119478A1 (en) * | 1997-05-30 | 2002-08-29 | Diagen Corporation | Methods for detection of nucleic acid sequences in urine |
| WO2006066353A1 (en) * | 2004-12-23 | 2006-06-29 | Human Genetic Signatures Pty Ltd | Detection of human papilloma virus |
| WO2007057669A2 (en) * | 2005-11-15 | 2007-05-24 | Genoid Kft. | Method of detecting pathogens |
| CN1814796A (zh) * | 2005-12-02 | 2006-08-09 | 浙江大学 | 一种用于26种人乳头瘤病毒的检测与分型的方法 |
| DE102006041970A1 (de) * | 2006-08-28 | 2008-03-06 | Genome Identification Diagnostics Gmbh | Verfahren und Mittel zum Nachweis von humanen Papillomaviren |
| EP2184368A1 (en) * | 2008-11-07 | 2010-05-12 | DKFZ Deutsches Krebsforschungszentrum | Diagnostic transcript and splice patterns of HPV16 in different cervical lesions |
-
2009
- 2009-10-26 CA CA2741762A patent/CA2741762C/en not_active Expired - Fee Related
- 2009-10-26 CN CN200980153183.8A patent/CN102333892B/zh not_active Expired - Fee Related
- 2009-10-26 JP JP2011534663A patent/JP2012507293A/ja active Pending
- 2009-10-26 WO PCT/US2009/062114 patent/WO2010051261A2/en not_active Ceased
- 2009-10-26 AU AU2009308943A patent/AU2009308943A1/en not_active Abandoned
- 2009-10-26 EP EP09797216.0A patent/EP2358915B1/en not_active Not-in-force
- 2009-10-26 CN CN201510671553.4A patent/CN105385784A/zh active Pending
- 2009-10-26 ES ES09797216.0T patent/ES2588251T3/es active Active
- 2009-10-26 US US13/126,081 patent/US8642261B2/en not_active Expired - Fee Related
-
2014
- 2014-02-04 US US14/172,793 patent/US9453265B2/en not_active Expired - Fee Related
-
2015
- 2015-01-27 JP JP2015013489A patent/JP6092906B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-25 US US15/218,177 patent/US20170016078A1/en not_active Abandoned
- 2016-08-19 HK HK16109959.2A patent/HK1221749A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110318727A1 (en) | 2011-12-29 |
| CN105385784A (zh) | 2016-03-09 |
| JP2012507293A (ja) | 2012-03-29 |
| HK1221749A1 (zh) | 2017-06-09 |
| US8642261B2 (en) | 2014-02-04 |
| JP2015130863A (ja) | 2015-07-23 |
| EP2358915A2 (en) | 2011-08-24 |
| CN102333892A (zh) | 2012-01-25 |
| US20140363807A1 (en) | 2014-12-11 |
| CN102333892B (zh) | 2015-11-25 |
| ES2588251T3 (es) | 2016-10-31 |
| HK1164940A1 (zh) | 2012-09-28 |
| WO2010051261A3 (en) | 2010-12-16 |
| US9453265B2 (en) | 2016-09-27 |
| CA2741762A1 (en) | 2010-05-06 |
| AU2009308943A1 (en) | 2010-05-06 |
| US20170016078A1 (en) | 2017-01-19 |
| WO2010051261A2 (en) | 2010-05-06 |
| JP6092906B2 (ja) | 2017-03-08 |
| EP2358915B1 (en) | 2016-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9453265B2 (en) | Method for detection of high risk human papillomavirus | |
| US20140051066A1 (en) | Hpv detection and quantification by real-time multiplex amplification | |
| WO1992001815A1 (en) | Method for the diagnosis of human pappiloma virus type 16 using the polymerase chain reaction | |
| Feoli‐Fonseca et al. | Human papillomavirus (HPV) study of 691 pathological specimens from Quebec by PCR‐direct sequencing approach | |
| US20110027778A1 (en) | Composition comprising an oligonucleotide mixture for improved detection of human papillomavirus genotypes | |
| JP5777338B2 (ja) | Ｈｐｖに起因する癌細胞の検出方法、組織が高度異形成以上の段階の組織であるか否かの判定方法及びそれらに用いるプライマーセット並びにキット | |
| US20150376725A1 (en) | HPV Detection in Urine | |
| US20030129585A1 (en) | Detection of human papillomaviruses | |
| Cornelissen et al. | Evaluation of different DNA‐DNA hybridisation techniques in detection of HPV 16 DNA in cervical smears and biopsies | |
| Tornesello et al. | Human papillomavirus infection in urine samples from male renal transplant patients | |
| HK1164940B (en) | A genetic marker for detection of human papillomavirus | |
| AU2003267861A2 (en) | Method for detecting and typing of cutaneous HPV and primers and probes for use therein | |
| Mardhia et al. | Role of Ureaplasma urealyticum and Ureaplasma parvum as Risk Factors for Cervical Dysplasia with Human Papillomavirus | |
| WO2014029851A1 (en) | Diagnosis of hpv-induced cancer | |
| CN121087230A (zh) | 中高危型人乳头瘤病毒的引物组合、探针组、检测产品及其应用 | |
| Soltanahmadi et al. | MOLECULAR DIAGNOSIS OF HUMAN PAPILLOMAVIRUS (HPV) GENOTYPES IN TEHRAN CITY | |
| Walboomers et al. | Detection of Genital Human Papilloma Virus Infections by the Polymerase Chain Reaction | |
| Gissmann | The Discovery of HPV and its Clinical Implications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20141015 |
|
| MKLA | Lapsed |
Effective date: 20191028 |